Three oral and 12 poster presentations demonstrate breadth and progress of AskBio’s gene therapy research and development ...

The 20th annual John Heinrichs Scholarly and Creative Activity Days (SACAD) was held on April 24. Despite an early threat of ...

Discover groundbreaking research and presentations from leading companies at the ARVO 2025 Annual Meeting, advancing ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...

Codexis to showcase data that demonstrate the scalability and reproducibility of its enzymatic siRNA manufacturing processes Three CDMO presentations to feature data on performance of Codexis ...

This "trial-in-progress” presentation will focus on the design of the ongoing expansion portion of Mersana's Phase 1 clinical trial of Emi-Le that is actively enrolling patients with triple negative ...

VectorY Therapeutics (VectorY), a biotechnology company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, today announced that it will have four feat ...

A poster presentation will highlight new translational ... In addition, two trials-in-progress presentations will showcase the design and scientific rationale of ongoing clinical studies evaluating ...

This “trial-in-progress” presentation will focus on the design of the ongoing expansion portion of Mersana’s Phase 1 clinical trial of Emi-Le that is actively enrolling patients with triple ...